Pharming Group to report third quarter 2025 financial results and provide business update on November 6
Pharming Group (Euronext: PHARM / Nasdaq: PHAR) will report preliminary unaudited Q3 2025 financial results and provide a business update on Thursday, November 6, 2025.
Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET / 07:30 ET. Investors must register in advance for the conference call or webcast; dial-in attendees will receive a unique PIN and only dial-in participants can ask questions. The webcast will be available on the company’s Investors/Financial Documents page and a replay will be posted shortly after the event.
Pharming Group (Euronext: PHARM / Nasdaq: PHAR) riporterà i risultati finanziari preliminari non auditati del Q3 2025 e fornirà un aggiornamento sull’andamento aziendale il giovedì 6 novembre 2025.
La direzione terrà una conferenza telefonica e webcast per analisti e investitori nello stesso giorno alle 13:30 CET / 07:30 ET. Gli investitori devono registrarsi in anticipo per la conferenza telefonica o la webcast; gli utenti dial-in riceveranno un PIN univoco e solo i partecipanti dial-in possono porre domande. La webcast sarà disponibile sulla pagina degli Investitori/Documenti Finanziari della società e una replica sarà pubblicata poco dopo l’evento.
Pharming Group (Euronext: PHARM / Nasdaq: PHAR) informará los resultados financieros preliminares no auditados del tercer trimestre de 2025 y proporcionará una actualización comercial el jueves 6 de noviembre de 2025.
La dirección realizará una llamada de conferencia y webcast para analistas e inversores el mismo día a las 13:30 CET / 07:30 ET. Los inversionistas deben registrarse con antelación para la conferencia telefónica o webcast; los asistentes por dial-in recibirán un PIN único y solo los participantes por dial-in pueden hacer preguntas. El webcast estará disponible en la página de Inversores/Documentos Financieros de la empresa y se publicará una réplica poco después del evento.
Pharming Group (Euronext: PHARM / Nasdaq: PHAR)는 예비 비감사 2025년 3분기 재무실적를 발표하고 2025년 11월 6일 목요일에 비즈니스 업데이트를 제공할 예정입니다.
경영진은 같은 날 분석가 및 투자자를 위한 컨퍼런스 콜 및 웹캐스트를 CEST 13:30 / ET 07:30에 주최합니다. 투자자들은 컨퍼런스 콜 또는 웹캐스트에 사전에 등록해야 하며 dial-in 참가자는 고유 PIN을 받게 되며 전화로만 질문할 수 있습니다. 웹캐스트는 회사의 투자자/재무문서 페이지에서 이용 가능하며 이벤트 직후에 재방송이 게시될 예정입니다.
Pharming Group (Euronext : PHARM / Nasdaq : PHAR) publiera les résultats financiers préliminaires non audités du T3 2025 et fournira une mise à jour commerciale le jeudi 6 novembre 2025.
La direction animera une conférence téléphonique et une diffusion webcast pour les analystes et les investisseurs le même jour à 13:30 CET / 07:30 ET. Les investisseurs doivent s’inscrire à l’avance pour la conférence téléphonique ou la diffusion webcast ; les participants par dial-in recevront un code PIN unique et seuls les participants en dial-in pourront poser des questions. La diffusion webcast sera disponible sur la page Investisseurs/Documents financiers de l’entreprise et une rediffusion sera publiée peu après l’événement.
Pharming Group (Euronext: PHARM / Nasdaq: PHAR) wird vorläufige nicht testierte Q3 2025 Finanzresultate berichten und am Donnerstag, 6. November 2025 ein Geschäftsupdate bereitstellen.
Das Management wird am selben Tag eine Telefonkonferenz und Webcast für Analysten und Investoren ausrichten, um 13:30 CET / 07:30 ET zu sprechen. Investoren müssen sich im Voraus für die Telefonkonferenz oder den Webcast anmelden; Dial-in-Teilnehmer erhalten eine eindeutige PIN und nur Dial-in-Teilnehmer können Fragen stellen. Der Webcast wird auf der Seite der Investoren/Finanzdokumente des Unternehmens verfügbar sein, und eine Wiedergabe wird kurz nach der Veranstaltung veröffentlicht.
Pharming Group (Euronext: PHARM / Nasdaq: PHAR) ستعلن عن نتائج مالية أولية غير مدققة للربع الثالث من 2025 وتقدم تحديثاً للأ business في الخميس 6 نوفمبر 2025.
ستجري الإدارة مكالمة مؤتمرات وبثاً عبر الإنترنت للمحللين والمستثمرين في اليوم نفسه في 13:30 بتوقيت وسط أوروبا / 07:30 بتوقيت شرق الولايات المتحدة. يجب على المستثمرين التسجيل مقدماً للمكالمة الهاتفية أو البث؛ سيستلم المشاركون عبر الاتصال الهاتفي رمز تعريف فريد ولا يمكن إلا للمشاركين عبر الاتصال الهاتفي طرح الأسئلة. سيكون البث عبر الإنترنت متاحاً على صفحة المستثمرين/الوثائق المالية للشركة وسيتم نشر إعادة للمشاهدة بعد الحدث بقليل.
Pharming Group (Euronext: PHARM / Nasdaq: PHAR) 将公布初步未经审计的 2025年第三季度财务业绩 并在 2025年11月6日，星期四 提供业务更新。
管理层将于同日举办面向分析师和投资者的电话会议和 webcast，时间为 13:30 CET / 07:30 ET。投资者须事先注册参加电话会议或 webcast；通过拨号加入的参与者将收到一个唯一的 PIN，只有拨号参与者可以提问。网络广播将可在公司投资者/财务文件页面查看，活动结束后不久将发布回放。
- None.
- None.
Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 and provide a business update on Thursday, November 6, 2025.
Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/07:30 am ET.
To participate in the conference call or to watch the live webcast, please register in advance using the links below.
Conference call registration:
https://register-conf.media-server.com/register/BI1b6a1a63294c427f91ab7b24a7c6484b
Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.
Please note, the Company will only take questions from dial-in attendees.
Webcast registration:
https://edge.media-server.com/mmc/p/vb724dzx
The webcast will also be accessible on the Pharming website at Investors/Financial Documents, and a replay will be available shortly after the event.
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Attachment
FAQ
When will Pharming (PHARM) report Q3 2025 results?
What time is the Pharming Q3 2025 conference call and webcast?
How can investors join the Pharming Q3 2025 webcast or conference call?
Can non-dial-in viewers ask questions during the Pharming Q3 2025 event?
Where will the Pharming Q3 2025 webcast be posted after the event?
Are the Q3 2025 financial results from Pharming final or preliminary?
